EP4720111A1 - Zusammensetzungen mit p53-peptid-amphiphilen und verfahren zur verwendung davon - Google Patents

Zusammensetzungen mit p53-peptid-amphiphilen und verfahren zur verwendung davon

Info

Publication number
EP4720111A1
EP4720111A1 EP24812001.6A EP24812001A EP4720111A1 EP 4720111 A1 EP4720111 A1 EP 4720111A1 EP 24812001 A EP24812001 A EP 24812001A EP 4720111 A1 EP4720111 A1 EP 4720111A1
Authority
EP
European Patent Office
Prior art keywords
peptide
seq
amino acid
mutant
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24812001.6A
Other languages
English (en)
French (fr)
Inventor
Peter C. DEMUTH
Christopher M. HAQQ
Martin P. STEINBUCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elicio Therapeutics Inc
Original Assignee
Elicio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elicio Therapeutics Inc filed Critical Elicio Therapeutics Inc
Publication of EP4720111A1 publication Critical patent/EP4720111A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
EP24812001.6A 2023-05-25 2024-05-24 Zusammensetzungen mit p53-peptid-amphiphilen und verfahren zur verwendung davon Pending EP4720111A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363504262P 2023-05-25 2023-05-25
US202363546841P 2023-11-01 2023-11-01
PCT/US2024/031064 WO2024243542A1 (en) 2023-05-25 2024-05-24 Compositions containing p53 peptide amphiphiles and methods of use thereof

Publications (1)

Publication Number Publication Date
EP4720111A1 true EP4720111A1 (de) 2026-04-08

Family

ID=93589845

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24812001.6A Pending EP4720111A1 (de) 2023-05-25 2024-05-24 Zusammensetzungen mit p53-peptid-amphiphilen und verfahren zur verwendung davon

Country Status (7)

Country Link
EP (1) EP4720111A1 (de)
JP (1) JP2026518761A (de)
KR (1) KR20260028688A (de)
CN (1) CN121605121A (de)
AU (1) AU2024277363A1 (de)
MX (1) MX2025013951A (de)
WO (1) WO2024243542A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11623002B2 (en) * 2016-01-29 2023-04-11 Elicio Therapeutics, Inc. ALK polypeptides and methods of use thereof
JP7391015B2 (ja) * 2017-09-29 2023-12-04 アメリカ合衆国 Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法
WO2023022973A2 (en) * 2021-08-16 2023-02-23 Elicio Therapeutics, Inc. Compositions containing polynucleotide amphiphiles and methods of use thereof

Also Published As

Publication number Publication date
AU2024277363A9 (en) 2025-12-18
WO2024243542A1 (en) 2024-11-28
JP2026518761A (ja) 2026-06-09
KR20260028688A (ko) 2026-03-04
AU2024277363A1 (en) 2025-12-11
MX2025013951A (es) 2026-03-02
CN121605121A (zh) 2026-03-03

Similar Documents

Publication Publication Date Title
CA2884677C (en) Cell penetrating peptides derived from the epstein barr virus, compositions and methods thereof
CN112118847B (zh) 包含突变kras序列和脂质的化合物及其用途
US20250134992A1 (en) Compositions containing polynucleotide amphiphiles and methods of use thereof
AU2024277363A9 (en) Compositions containing p53 peptide amphiphiles and methods of use thereof
WO2021123232A1 (en) Nucleic acid vaccination using neo-epitope encoding constructs
WO2024243540A1 (en) Compositions containing braf peptide amphiphiles and methods of use thereof
EP3993820A1 (de) Antikörper zum humanen programmierten zelltod-pd-1-rezeptor
AU2024263122A1 (en) Compositions containing polynucleotide and polypeptide amphiphiles and methods of use thereof
EP1436002B1 (de) Verwendung von peptidvektoren zur verbesserung der immunantwort gegen antigene
RU2773273C2 (ru) Неоантигены и способы их использования
HK40043265B (en) Compounds including a mutant kras sequence and a lipid and uses thereof
WO2024040264A1 (en) Compositions and methods for targeting dendritic cell lectins
ES2734561T3 (es) Péptidos de penetración celular
CN119894531A (zh) Tau肽免疫原构建体
HK40043265A (en) Compounds including a mutant kras sequence and a lipid and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR